Disease · HP_0002788
Recurrent upper respiratory tract infections
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Recurrent upper respiratory tract infections. Diseases, record HP_0002788. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002788
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Recurrent upper respiratory tract infections
- Open Targets ID
- HP_0002788
- Other names
Frequent upper respiratory infections, Frequent upper respiratory tract infections, Recurrent URI, Recurrent colds, Recurrent upper respiratory and lower respiratory infections, Recurrent upper respiratory infection, Recurrent upper respiratory infections, Upper respiratory tract infections, Upper respiratory tract infections, recurrent
- Highest stage of its drugs
- Phase 3, for 6 of its 16 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs16
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| GUAIFENESIN | CHEMBL980 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DOXYLAMINE SUCCINATE | CHEMBL1200392 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ECHINACEA, UNSPECIFIED | CHEMBL4297943 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| ETAFEDRINE HYDROCHLORIDE | CHEMBL2106678 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LOXOPROFEN | CHEMBL19299 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PELUBIPROFEN | CHEMBL69308 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MEMANTINE HYDROCHLORIDE | CHEMBL1699 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| SISUNATOVIR | CHEMBL4297497 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VAPENDAVIR | CHEMBL2062774 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXTROMETHORPHAN | CHEMBL52440 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 16
See all 16 drugsTargets11
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GRIN2A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor subunit epsilon 1 antagonist | Phase 2 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| GRIN1 | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2B | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2904 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2905 | Drugs and targets |
| GRIN2D | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/2906 | Drugs and targets |
| GRIN3A | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/116443 | Drugs and targets |
| GRIN3B | Glutamate [NMDA] receptor | 1 | Glutamate [NMDA] receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/116444 | Drugs and targets |
| HRH1 | Histamine H1 receptor | 1 | Histamine H1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3269 | Drugs and targets |
1 to 10 of 11
See all 11 targetsTrials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01537081 | Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections | Phase 2/3 | 2,810 | 2013-09-12 | Acute Upper Respiratory Tract Infection | GUAIFENESIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01076153 | Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR | 760 | 2011-06-29 | Respiratory Tract Infection | CLARITHROMYCIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01075204 | Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER) | 335 | 2013-01-30 | Respiratory Tract Infection | CLARITHROMYCIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00029211 | A Trial of Echinacea in Children | Phase 3 | 600 | Common Cold | ECHINACEA, UNSPECIFIED | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01779271 | Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection | Phase 3 | 183 | Acute Upper Respiratory Infection, Fever | LOXOPROFEN, PELUBIPROFEN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00857987 | Effectiveness and Safety of the of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improvement of Symptoms Resulting From Acute Respiratory Infections. | Phase 3 | 174 | Upper Airway Infections | DOXYLAMINE SUCCINATE, ETAFEDRINE HYDROCHLORIDE, GUAIFENESIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00127686 | Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep | Phase 1 | 105 | Cough, Respiratory Tract Infections | DEXTROMETHORPHAN, HONEY | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05955885 | Effect of Over-the-counter NSAIDS on Cough Reflex Sensitivity in Patients with Upper Respiratory Tract Infections | Early phase 1 | 101 | Cough, Upper Respiratory Tract Infections | FLURBIPROFEN | Its record names the disease | ClinicalTrials.gov | |
| NCT04452799 | Hesperidin and Diosmin for Treatment of COVID-19 | Early phase 1 | 100 | Coronavirus Infection | DIOSMIN, HESPERIDIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04479657 | Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection | Early phase 1 | 60 | Upper Respiratory Tract Infection, Bacterial Infection, Chinese Medicine, Pediatric Acute Upper Respiratory Tract Infection | CEFUROXIME | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002788
GET https://conductscience.org/api/diseases/v1/HP_0002788/drugs